Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine Extension Study in Chinese Patients with Chronic Hepatitis B
NCT00646503Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Primary completion
- Sep 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by Novartis. Primary endpoints: Proportion of patients experiencing serious adverse events at Week 52 and Proportion of patients experiencing adverse events at Week 52. Started Mar 2008; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00646503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00646503.